ANTINSKY Dental Resins Achieve CE & MDR Certification for Global Regulatory Compliance

ANTINSKY Dental Guide   Resin and Temporary Dental Model Resin have recently obtained both CE marking and full conformity with the EU Medical Device Regulation (MDR 2017/745). This dual certification confirms that both products meet the EU’s stringent requirements for biocompatibility (per ISO 10993), clinical safety, material stability, manufacturing quality management (ISO 13485), and post-market surveillance. As a result, these resins are now authorized for legal placement on the European Union market and other jurisdictions recognizing MDR-compliant medical devices. They offer dental clinics, denture laboratories, and digital oral centers globally a compliant, high-performance, and clinically validated 3D printing material solution for precision-guided procedures and temporary restorations.

What is CE + MDR Dual Certification?   

CE marking is the mandatory conformity assessment indicating that a medical device meets the essential safety and performance requirements set forth in applicable EU directives and regulations. For dental resins classified as Class I (non-sterile, non-measuring) or Class IIa devices under MDR, CE marking signifies compliance with fundamental requirements related to design, formulation, manufacturing controls, labeling, and risk management.   

The MDR certification goes significantly beyond CE marking by mandating rigorous clinical evaluation, systematic biocompatibility testing (including cytotoxicity, sensitization, and irritation per ISO 10993-5, -10, and -23), robust technical documentation, proactive risk mitigation strategies, and adherence to a certified quality management system (QMS) aligned with ISO 13485:2016. It also requires transparency in traceability, post-market surveillance, and periodic safety update reporting.

Implications of CE + MDR Certification for ANTINSKY Dental Resins:   
• Full compliance with ISO 10993 series standards for oral mucosal contact, ensuring safety and low irritation potential;   
• Independent verification—by an EU Notified Body—of material composition, production processes, and QMS;   
• Legal market access across all 27 EU Member States and countries accepting MDR-aligned regulatory pathways;   
• Demonstrated fulfillment of core clinical requirements: sub-50 µm dimensional accuracy, high flexural strength (>80 MPa), excellent disinfection resistance (compatible with 75% ethanol, 0.5% sodium hypochlorite, and UV-C protocols), and minimal polymerization shrinkage (<2.5%).

II. Product-Specific Clinical Advantages   

Dental Guide Resin:   
• Exceptional rigidity and long-term dimensional stability: No measurable deformation after 90 days of ambient storage;   
• High-fidelity anatomical replication: Seamless integration with intraoral scan data; guide   margins exhibit ≤0.1 mm marginal discrepancy and drill hole positional accuracy within ±0.05 mm;   
• Clinically validated disinfection resistance: Maintains structural integrity and surface integrity after ≥10 cycles of standard clinical disinfection;   
• Optical clarity (transmittance >92% at 550 nm): Enables unobstructed intraoperative visualization and real-time procedural guidance.

Temporary Dental Model Resin:   
• Natural tooth-shade matching (A1–A3 chromatic scale per VITA Classical Guide): Achieves esthetic harmony and facilitates seamless polishing without surface clouding or pigment leaching;   
• Superior mechanical performance: Flexural strength ≥110 MPa and wear resistance exceeding ISO 20795-1 requirements for provisional materials;   
• High-fidelity model reproduction: Surface detail resolution <20 µm; dimensional deviation <0.08% across full-arch scans;   
• Low polymerization shrinkage (<2.2%) and negligible volatile organic compound (VOC) emission: Enhances operator comfort and patient tolerance during intraoral use.

III. Strategic Value: Addressing Procurement and Clinical Decision Drivers   

Key criteria influencing procurement and clinical adoption of dental resins include:   
1. Regulatory assurance: Valid CE marking and full MDR compliance—including Notified Body involvement and technical file review;   
2. Mechanical reliability: Structural integrity of surgical guides under occlusal load and retention stability of temporary prostheses over multi-week wear periods;   
3. Digital workflow compatibility: Precision alignment with STL/Ply data, edge fidelity, polishability, and inter-layer adhesion consistency;   
4. Biocompatibility and patient safety: Absence of cytotoxicity, sensitization, or mucosal irritation under simulated clinical conditions;   
5. Global supply chain readiness: Fully documented, export

compliant manufacturing with harmonized labeling, UDI assignment, and logistics support for cross-border distribution.

ANTINSKY’s CE- and MDR-certified dental resins directly address each of these priorities—establishing them as a trusted, regulatory-first choice for digitally enabled dental practices and laboratories committed to clinical excellence and compliance integrity.

About ANTINSKY:   

ANTINSKY is a specialized developer and manufacturer of industrial-grade and medical-grade 3D printing photopolymers. With core R&D focus on dimensional stability, printing precision, and cost-efficient scalability, the company delivers validated solutions across dental, industrial prototyping, and functional end-use applications.

The successful certification of these dental resins under both CE and MDR represents a strategic milestone—affirming ANTINSKY’s commitment to global regulatory alignment, clinical relevance, and sustainable advancement of additive manufacturing in healthcare.